Jules Cotard first described this disorder at a lecture he was giving in Paris in 1880. In this lecture, Cotard referred to the disorder as le délire de negation, or negation delirium. He used a woman to serve as an example that the disorder has varying degrees of severity, ranging from mild to severe. The woman that he described was in denial about the existence of God, the Devil, several parts of her body, and her need to eat. She went on to believe that she was eternally damned and could no longer die a natural death. Ironically, she died of starvation.
Cotard Delusion is prevalent in cases of psychosis such as schizophrenia and bipolar disorder. Depression, however, is always existent in patients with Cotard Delusion. In rare cases, it has resulted from an adverse drug reaction to antiviral medications that are used primarily to treat shingles and genital herpes.
A patient with Cotard Delusion will show behavior identical or similar to isolating him or herself to an area, such as a bed, for extended amounts of time. The victim will most likely begin to neglect personal hygiene, begin to lose vocal inflections and spontaneous facial expressions, and deny emotive differences. The depression is one that does not cause suicidal ideation, due to the victim’s belief that he or she is already dead.
Cotard Delusion is similar to Capgras’ Delusion as they are both thought to result from a disconnect between the areas of the brain that recognize faces, and the area that responds emotionally to a recognized face.
Cotard Delusion is prevalent in cases of psychosis, such as depression, schizophrenia, and bipolar disorder. It has also resulted as the result of an adverse drug reaction to antiviral medications that are used primarily to treat shingles and genital herpes.
Treatment for Cotard Delusion is difficult and very limited; there has been only one therapy that has shown promise: electroconvulsive therapy, or ECT. ECT is a therapy in which seizures are electrically induced onto medically desensitized patients for therapeutic effect. Along with ECT comes the risk of severe memory loss and responsibility. If ECT is not followed by drugs or further ECT, or the benefits will be lost. Also, the treatment cannot be administered without an informed consent by the patient that states the risks, benefits, and reason for treatment.
Following ECT, the medication that the patient is prescribed to maintain benefits gained is very important. Generally, the patient is given Olanzapine, a drug used to treat conditions such as anxiety and eating disorders, and Escitalopram, used to treat anxiety and depression. There have been other cases involving different drugs that share the same general principal.